MASI Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of -45.89% compared to Masimo's net margin of -19.35%. Masimo's return on equity of -39.91% beat iRhythm Technologies's return on equity of -112.03%.

Masimo has a consensus price target of $182.07, signalling upside risk potential of 12.05%. On the other hand iRhythm Technologies has an analysts' consensus of $140.42 which suggests that it could fall by -0.06%. Given that Masimo has higher upside potential than iRhythm Technologies, analysts believe Masimo is more attractive than iRhythm Technologies.

Masimo has a beta of 1.229, which suggesting that the stock is 22.855% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.343, suggesting its more volatile than the S&P 500 by 34.347%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $372M, which are larger than iRhythm Technologies quarterly revenues of $158.7M. Masimo's net income of -$170.7M is lower than iRhythm Technologies's net income of -$30.7M. Notably, Masimo's price-to-earnings ratio is 116.80x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.47x versus 7.12x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of -45.89% compared to Masimo's net margin of 8.48%. Masimo's return on equity of -39.91% beat Merit Medical Systems's return on equity of 9.19%.

Masimo has a consensus price target of $182.07, signalling upside risk potential of 12.05%. On the other hand Merit Medical Systems has an analysts' consensus of $108.55 which suggests that it could grow by 14.22%. Given that Merit Medical Systems has higher upside potential than Masimo, analysts believe Merit Medical Systems is more attractive than Masimo.

Masimo has a beta of 1.229, which suggesting that the stock is 22.855% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.439%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $372M, which are larger than Merit Medical Systems quarterly revenues of $355.4M. Masimo's net income of -$170.7M is lower than Merit Medical Systems's net income of $30.1M. Notably, Masimo's price-to-earnings ratio is 116.80x while Merit Medical Systems's PE ratio is 46.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.47x versus 4.11x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -45.89% compared to Masimo's net margin of 6.22%. Masimo's return on equity of -39.91% beat Insulet's return on equity of 36.9%.

Masimo has a consensus price target of $182.07, signalling upside risk potential of 12.05%. On the other hand Insulet has an analysts' consensus of $332.35 which suggests that it could grow by 2.25%. Given that Masimo has higher upside potential than Insulet, analysts believe Masimo is more attractive than Insulet.

Masimo has a beta of 1.229, which suggesting that the stock is 22.855% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $372M, which are smaller than Insulet quarterly revenues of $569M. Masimo's net income of -$170.7M is lower than Insulet's net income of $35.4M. Notably, Masimo's price-to-earnings ratio is 116.80x while Insulet's PE ratio is 58.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.47x versus 10.94x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -45.89% compared to Masimo's net margin of 28.26%. Masimo's return on equity of -39.91% beat ResMed's return on equity of 25.76%.

Masimo has a consensus price target of $182.07, signalling upside risk potential of 12.05%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 8.05%. Given that Masimo has higher upside potential than ResMed, analysts believe Masimo is more attractive than ResMed.

Masimo has a beta of 1.229, which suggesting that the stock is 22.855% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Masimo pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo quarterly revenues are $372M, which are smaller than ResMed quarterly revenues of $1.3B. Masimo's net income of -$170.7M is lower than ResMed's net income of $365M. Notably, Masimo's price-to-earnings ratio is 116.80x while ResMed's PE ratio is 27.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.47x versus 7.19x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.